Education
About Us
Working with TipRanks
Follow Us
Revolution Medicines (RVMD)
NASDAQ:RVMD
RVMD Stock Chart & Stats
$98.40
$0.52(1.17%)
At close: 4:00 PM EST
$98.40
$0.52(1.17%)
Day’s Range― - ―
52-Week Range$29.17 - $124.49
Previous CloseN/A
Volume180.68K
Average Volume (3M)2.53M
Market Cap
$19.50B
Enterprise Value$19.28B
Total Cash (Recent Filing)$2.03B
Total Debt (Recent Filing)$158.70M
Price to Earnings (P/E)―
Beta1.02
Next Earnings
May 11, 2026EPS Estimate
-1.81Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.86
Shares Outstanding198,173,400
10 Day Avg. Volume2,797,105
30 Day Avg. Volume2,525,727
Financial Highlights & Ratios
PEG Ratio-0.20
Price to Book (P/B)9.28
Price to Sales (P/S)0.00
P/FCF Ratio-16.57
Enterprise Value/Market Cap0.99
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.27K
Enterprise Value/Ebitda-16.97
Forecast
1Y Price Target
$140.07Price Target Upside42.35% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
EPS Forecast (FY)-7.57
Revenue Forecast (FY)$33.68M
Bulls Say, Bears Say
Bulls Say
Clinical Trial CatalystA pivotal readout from the RASolute 302 trial for daraxonrasib could support a regulatory submission and drive significant upside if overall survival results confirm the early improvements seen versus standard chemotherapy.
Commercial Readiness And Cash RunwayManagement's commercial buildout, including regional sales leadership and plans to hire field teams, paired with an at-the-market equity program, should extend cash runway and position the company to commercialize independently if trials succeed.
Pipeline Expansion And PartnershipsAdvancement of additional candidates, initiation of a bispecific program, a new G12V inhibitor entering human testing, and a collaboration with a major pharma to explore combinations broaden the franchise and increase potential strategic value.
Bears Say
Reduced Takeover LikelihoodThe company's move to pursue standalone commercialization and to raise capital publicly has lowered perceived takeover probability, potentially eliminating acquisition upside for investors.
Reimbursement And Adoption RiskAnalyst cautions that payer coverage and access barriers could limit patient uptake and slow real-world adoption of daraxonrasib despite clinical interest and favorable trial signals.
Rising Operating ExpensesManagement indicated materially higher operating expenses from expanded clinical development, manufacturing, and commercial preparations, heightening cash burn concerns and the need for future financing.
Revolution Medicines News
RVMD FAQ
What was Revolution Medicines’s price range in the past 12 months?
Revolution Medicines lowest stock price was $29.17 and its highest was $124.49 in the past 12 months.
What is Revolution Medicines’s market cap?
Revolution Medicines’s market cap is $19.50B.
When is Revolution Medicines’s upcoming earnings report date?
Revolution Medicines’s upcoming earnings report date is May 11, 2026 which is in 63 days.
How were Revolution Medicines’s earnings last quarter?
Revolution Medicines released its earnings results on Feb 25, 2026. The company reported -$1.86 earnings per share for the quarter, missing the consensus estimate of -$1.581 by -$0.279.
Is Revolution Medicines overvalued?
According to Wall Street analysts Revolution Medicines’s price is currently Undervalued.
Does Revolution Medicines pay dividends?
Revolution Medicines does not currently pay dividends.
What is Revolution Medicines’s EPS estimate?
Revolution Medicines’s EPS estimate is -1.81.
How many shares outstanding does Revolution Medicines have?
Revolution Medicines has 198,173,400 shares outstanding.
What happened to Revolution Medicines’s price movement after its last earnings report?
Revolution Medicines reported an EPS of -$1.86 in its last earnings report, missing expectations of -$1.581. Following the earnings report the stock price went down -1.056%.
Which hedge fund is a major shareholder of Revolution Medicines?
Currently, no hedge funds are holding shares in RVMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Revolution Medicines Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$140.07 (42.35% Upside)
$140.07 (42.35% Upside)
Blogger Sentiment
Neutral
RVMD Sentiment 60%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 977.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $607.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 1.8%
Last 30 Days ▲ 1.4%
Last 30 Days ▲ 1.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
150.89%
12-Months-Change
Fundamentals
Return on Equity
-58.07%
Trailing 12-Months
Asset Growth
-7.49%
Trailing 12-Months
Company Description
Revolution Medicines
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
RVMD Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong clinical and operational momentum: multiple registrational trials, regulatory designations (Breakthrough Therapy and a commissioner priority voucher), promising early clinical data (notably zoldonrasib combination responses), new compounds entering the clinic, and a solid cash position supplemented by a large Royalty Pharma commitment. Offsetting these positives are substantially higher R&D and G&A spending, a materially wider net loss, and elevated 2026 operating expense guidance as the company scales clinical and commercial activities. Clinical uncertainties remain (OS-driven readout timing, potential crossover risk, and difficult CRC biology), but the balance of progress and funding to execute the plan led management to accelerate investments. Overall, progress and available capital appear to outweigh the near-term financial drag from higher expenses.View all RVMD earnings summariesRVMD Stock 12 Month Forecast
Average Price Target
$140.07
▲(42.35% Upside)
Technical Analysis
Ownership Overview
2.25% Insiders
23.30% Mutual Funds
9.84% Other Institutional Investors
52.46% Public Companies and Individual Investors